The Complaint alleges Defendants provided these disclosures to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state impact of the Warning Letter on Viatris' financials; notably, Defendants did not disclose precisely when the inspection occurred, how long the remediation efforts had been implemented, or the financial impact of the existing and continued remediation efforts; Defendants further notably failed to disclose which products were subject to the FDA Warning Letter, which products were subject to exemptions, and the significance of the restricted products with respect to the Company's existing financials and future projections, and for which the Company believed it would obtain exemptions. The Complaint alleges that such statements, absent these material facts, caused Plaintiff and other shareholders to purchase Viatris' securities at artificially inflated prices.